Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors as of Dec. 31, 2022

Portfolio Holdings for Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors holds 17 positions in its portfolio as reported in the December 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Day One Biopharmaceuticals Common Stock (DAWN) 19.6 $163M 7.6M 21.52
Kymera Therapeutics Common Stock (KYMR) 18.0 $149M 6.0M 24.96
Dyne Therapeutics Common Stock (DYN) 13.8 $114M 9.9M 11.59
Vigil Neuroscience Common Stock (VIGL) 8.8 $73M 5.8M 12.50
Disc Medicine Common Stock (IRON) 8.3 $69M 3.5M 19.89
Aerovate Therapeutics Common Stock (AVTE) 7.1 $59M 2.0M 29.30
Replimune Group Common Stock (REPL) 6.9 $57M 2.1M 27.20
Third Harmonic Bio Common Stock (THRD) 5.6 $47M 11M 4.30
Akero Therapeutics Common Stock (AKRO) 3.9 $33M 594k 54.80
Generation Bio Common Stock (GBIO) 3.9 $33M 8.3M 3.93
Ikena Oncology Common Stock (IKNA) 1.6 $13M 5.0M 2.66
Xilio Therapeutics Common Stock (XLO) 0.9 $7.4M 2.8M 2.69
F-star Therapeutics Common Stock 0.5 $3.8M 600k 6.32
Avrobio Common Stock (AVRO) 0.4 $3.2M 4.5M 0.71
Viridian Therapeutics Common Stock (VRDN) 0.3 $2.6M 90k 29.21
Spero Therapeutics Common Stock (SPRO) 0.2 $1.8M 1.0M 1.73
Magenta Therapeutics Common Stock 0.2 $1.4M 3.5M 0.40